This article first appeared on GuruFocus .
Release Date: September 28, 2026
For the complete transcript of the earnings call, please refer to the full earnings call transcript .
Positive Points
-
Inventiva SA ( IVEVF )'s lanifibranor is a differentiated once-daily oral therapy targeting both metabolic and hepatic drivers of MASH, with FDA breakthrough therapy and fast-track designations.
-
In the Phase 2b NATIVE trial, lanifibranor achieved an 18% placebo-adjusted improvement in fibrosis, 26% MASH resolution, and 24% composite endpoint response after only six months.
-
The Phase 3 NATIV3 trial is fully enrolled with 1,009 patients in the main cohort, and top-line data is expected in Q4 2026, keeping the company on track for a potential NDA submission in H1 2027.
-
Inventiva SA ( IVEVF ) strengthened its balance sheet with EUR233.9 million in cash and equivalents as of June 30, 2026, extending cash runway through key milestones and potentially into Q1 2028.
-
The MASH market is large and growing, with an estimated 18 million Americans affected and a market potential expected to exceed $15 billion by 2035, representing a significant opportunity for lanifibranor if approved.
Negative Points
-
Lanifibranor's adverse event profile includes weight gain, edema, and hemoglobin decline, which, although attenuated compared to full TZD agonists, may still impact tolerability and commercial adoption.
-
The Phase 3 NATIV3 trial enrolled a higher proportion of F3 patients and more diabetic patients compared to Phase 2b, which could potentially affect efficacy outcomes and placebo response rates.
-
There is uncertainty regarding the impact of GLP-1 and SGLT2 inhibitor drop-ins during the trial, and while sensitivity analyses are planned, these factors could confound the primary endpoint results.
-
Inventiva SA ( IVEVF ) has not provided guidance on key top-line data components, such as weight gain and edema rates, leaving investors uncertain about the full safety and tolerability profile.
-
The company faces significant competition in the MASH space, and its patient diagnosis estimate of 374,000 F2/F3 patients is lower than some competitor estimates, which may indicate a more conservative market opportunity assessment.
Q & A Highlights
Q: If both doses of lanifibranor show statistically significant results in the NATIV-3 trial, would it make commercial sense to move both forward? And how do you reconcile the strong histological benefit of the higher dose with the similar non-invasive test (NIT) results between the two doses? A: CEO Andrew Obenshain stated that if both doses are statistically significant, it would make sense to bring both to market, depending on the data. A lower dose could be for earlier-stage, less urgent patients, while a higher dose could be for those needing more efficacy, provided tolerability is acceptable. CMO Dr. Jason Campagna added that in the Phase IIb trial, histology endpoints tracked well with most, but not all, biomarkers. For example, PRO-C3 (new scar formation) tracked well with the 1,200 mg dose. He noted that liver stiffness (TE) results were at the lower end of the range seen across trials, likely due to the early timepoint (6 months) and confounding from fluid retention, a known effect of PPAR gamma. He expects that with longer treatment (18 months), the underlying fibrosis improvement will dominate the signal.
Q: What information do you have on a blinded basis regarding weight gain in the NATIV-3 study, and what are your expectations for potential weight gain, given that physicians may have a higher bar for a drug with this side effect? A: CMO Dr. Jason Campagna explained that in a separate Phase 2 trial in scleroderma patients (non-metabolic), weight gain was similar to the MASH trial up to 6 months, then plateaued and remained stable through 48 weeks. He noted that in the NATIV Phase IIb trial, about half of patients had no weight gain (defined as >5% change). Among those who did, only about 10% of adverse event reports were related to weight gain, and it was not a primary driver of discontinuation. CEO Andrew Obenshain added that this suggests weight gain is not a major impediment to patients staying on treatment.
Q: Regarding edema, a known tolerability issue, what level and severity becomes unacceptable to NASH patients, and how does this risk-benefit compare to the potential fluid load? A: CEO Andrew Obenshain stated that edema is mechanistically understood and consistent with PPAR gamma pharmacology, making physicians experienced with pioglitazone comfortable managing it. He noted that it can be mitigated with an SGLT2 inhibitor if needed. CMO Dr. Jason Campagna added that the unadjusted prevalence of edema in the Phase IIb trial was 7-10%, with drug-related edema at about 2%, which is much lower than the 20-25% seen with pioglitazone. He characterized the events as generally mild to moderate, mostly peripheral, and not a primary driver of discontinuation. He believes the profile is commercially attractive, especially with the addition of a potential 18% fibrosis improvement.
Q: How do you expect the higher proportion of F3 patients enrolled in NATIV-3 compared to NATIV-2 to impact efficacy in both the drug and placebo arms? And how might the ~10% GLP-1 drop-in rate affect outcomes? A: CEO Andrew Obenshain explained that the Phase 3 trial enrolled more patients in the U.S., where there is more diabetes and F3 disease. He noted that when F1 patients were removed from the Phase 2 data, the response rate in F2/F3 patients was slightly better, giving confidence. He also stated that the GLP-1 drop-ins were at non-MASH doses and are not anticipated to impact the trial. CMO Dr. Jason Campagna added that there is no biological difference between F2 and F3 disease, just a more advanced version. He highlighted that lanifibranor has direct antifibrotic actions on hepatic stellate cells, which are independent of extrahepatic factors like weight loss. He also noted that the 18-month duration should allow enough time to see an effect in F3 patients, and that drugs like FGF21 analogs have shown similar efficacy in F2/F3 patients.
Q: Can you discuss the biopsy completion rate in the trial and whether it is tracking in line with recent Phase 3 MASH trials? Also, mechanistically, why does weight gain plateau for lanifibranor and not for pioglitazone? A: CEO Andrew Obenshain stated that the trial was powered to tolerate up to a 30% dropout rate, and as of April/May 2025, the dropout rate was comfortably below 30%. He did not provide further guidance. Regarding the weight gain plateau, CMO Dr. Jason Campagna explained that it is due to the partial PPAR gamma agonism of lanifibranor (not a full agonist) and the pan-PPAR activity. The alpha and delta components increase glucose utilization by tissues, which prevents sugar from being stored as fat, helping to keep weight stable over time.
Q: How much importance should be placed on the magnitude of fibrosis improvement, independent of MASH resolution, and what level of response would convince you of a meaningful antifibrotic effect? A: CEO Andrew Obenshain stated that an 18% improvement in fibrosis (one stage or more) would be meaningful, as it would duplicate the Phase 2 results. He believes this profile would be differentiated for three key patient segments: F3 diabetics/high cardiometabolic risk, F3 non-diabetics, and F2 diabetics.
Q: How are you thinking about the design of the confirmatory outcomes trial, and are there any key learnings from ongoing studies that could help inform patient selection? A: CMO Dr. Jason Campagna stated that the confirmatory trial will focus on patients with compensated advanced chronic liver disease (CACLD) and clinically significant portal hypertension, who can be identified using non-invasive methods like liver stiffness and platelet counts. He noted that the ongoing NATIV-3 exploratory cohort includes 75-100 cirrhotic patients treated for at least 18 months (up to 4 years), which will provide valuable safety and pharmacology data. Additionally, completed Phase 1 trials, including a dedicated hepatic impairment study, support the safety of lanifibranor in this population.
Q: With the NATIV-3 top-line readout expected next quarter, what kind of data can we expect, specifically regarding treatment response in patients on GLP-1s or weight gain? And how do you expect the placebo response to evolve with the longer treatment duration? A: CEO Andrew Obenshain stated that the
For the complete transcript of the earnings call, please refer to the full earnings call transcript .
